FFAR1 and cancer: The GPR40 antagonist, GW100 resulted in growth inhibition in EOC cell line which means GPR40 is a potential target for cancer therapy.184 In addition, there is another small molecule antagonist DC260126 that targeted GPR40, but its application in cancer has not been reported yet.185